Tag Archives | melanoma market research

Understanding why melanoma patients develop resistance to PLX4032

Targeted therapies for metastatic melanoma such as PLX4032 (vemurafenib) have shown dramatic effects in patients. ¬†However, resistance to BRAF inhibitors such as PLX4032 soon develops. The result is a need to understand how resistance occurs due to cross talk and how to overcome this through a rational drug combination strategy. Sally Church on Pharma Strategy […]

Continue Reading

error: Content is protected !!